Skip to main content

60 DEGREES PHARMACEUTICALS, INC.

For the period ended Mar 31, 2025. Filed May 15, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 15, 2025

SXTP$0.52-4.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Consolidated Condensed Statements of Cash Flows

CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)

For the Three Months Ended March 31, · 2025 · 2024
CASH FLOWS FROM OPERATING ACTIVITIES
Net (Loss) Income$(1,877,301)$427,985
Adjustments to Reconcile Net (Loss) Income to Net Cash Used in Operating Activities:
Depreciation6,694407
Amortization10,1038,207
Amortization of ROU Asset-13,517
Amortization of Capitalized Share-Based Payments44,118125,368
Share-Based Compensation under Equity Incentive Plan142,645-
Change in Fair Value of Derivative Liabilities(5,105)(1,740,847)
Write-offs of Capitalized Patents-8,378
Changes in Operating Assets and Liabilities:
Accounts Receivable(1,495)(84,888)
Prepaid and Other Assets131,68961,841
Inventory(330,474)30,792
Accounts Payable and Accrued Liabilities261,90523,243
Accrued Interest, net19,855(791)
Reduction of Lease Liability-(13,650)
Net Cash Used in Operating Activities(1,597,366)(1,140,438)
CASH FLOWS FROM INVESTING ACTIVITIES
Capitalization of Patents(2,804)(726)
Purchases of Fixed Assets(2,678)-
Acquisition of Intangibles-(9,088)
Maturities of Short-Term Investments1,708,000-
Net Cash Provided by (Used in) Investing Activities1,702,518(9,814)
CASH FLOWS FROM FINANCING ACTIVITIES
Net Proceeds from January 2024 Offering-1,898,296
Net Proceeds from January 2025 Offering804,346-
Net Proceeds from February 2025 Offering908,627-
Shares Withheld for Net Share Settlement of Performance Bonuses(18,000)-
Proceeds from Exercise of Pre-Funded Warrants1,9264,995
Net Cash Provided by Financing Activities1,696,8991,903,291
Effect of Exchange Rate Changes on Cash(9,904)(824)
Change in Cash and Cash Equivalents1,792,147752,215
Cash and Cash Equivalents—Beginning of Period1,659,3532,142,485
Cash and Cash Equivalents—End of Period$3,451,500$2,894,700
NONCASH INVESTING/FINANCING ACTIVITIES
Fair Value of Warrants Issued to Underwriters$-$71,364
Purchases of Fixed Assets included in Accounts Payable$10,000$-
Gross Shares Issued for Annual Performance Bonuses$121,544$-
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.